<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vavuranakis, Manolis</style></author><author><style face="normal" font="default" size="100%">Lavda, Maria</style></author><author><style face="normal" font="default" size="100%">Vrachatis, Dimitrios</style></author><author><style face="normal" font="default" size="100%">Papaioannou, Theodore G</style></author><author><style face="normal" font="default" size="100%">Kalogeras, Konstantinos</style></author><author><style face="normal" font="default" size="100%">Kolokathis, Angelos-Michail</style></author><author><style face="normal" font="default" size="100%">Kariori, Maria</style></author><author><style face="normal" font="default" size="100%">Lilly, Scott</style></author><author><style face="normal" font="default" size="100%">Siasos, Gerasimos</style></author><author><style face="normal" font="default" size="100%">Oikonomou, Evangelos</style></author><author><style face="normal" font="default" size="100%">Toutouzas, Konstantinos</style></author><author><style face="normal" font="default" size="100%">Stasinopoulou, Myrsini</style></author><author><style face="normal" font="default" size="100%">Deliveliotis, Konstantinos</style></author><author><style face="normal" font="default" size="100%">Tousoulis, Dimitrios</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Impact of balloon aortic valvuloplasty on transcatheter aortic valve implantation with self-expandable valve.</style></title><secondary-title><style face="normal" font="default" size="100%">J Cardiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">J Cardiol</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style  face="normal" font="default" size="100%">Aortic valve</style></keyword><keyword><style  face="normal" font="default" size="100%">Aortic Valve Stenosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Balloon Valvuloplasty</style></keyword><keyword><style  face="normal" font="default" size="100%">Combined Modality Therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Self Expandable Metallic Stents</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcatheter Aortic Valve Replacement</style></keyword><keyword><style  face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2017 Jan</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">69</style></volume><pages><style face="normal" font="default" size="100%">245-252</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND: Balloon aortic valvuloplasty (BAV) has been used prior to valve implantation of a self-expandable valve as part of the transcatheter aortic valve implantation (TAVI) procedure. We aimed to evaluate the impact of BAV prior to TAVI.

METHODS: We retrospectively studied 203 consecutive patients who were treated either with (pre-BAV-TAVI group) or without BAV (D-TAVI group). Implantation depth (ID) was angiographically measured at non-coronary cusp (NCC) and left coronary cusp (LCC) at: the starting point (stage-1), before (stage-2), and after (stage-3) final bioprosthesis release. Paravalvular regurgitation (PVR) and 1-year clinical follow-up were recorded.

RESULTS: Overall, from stage-1 to stage-3, prosthesis migrated toward the left ventricle, in both cusps and groups. At NCC a forward migration was observed from stage-1 to stage-2 in both groups (p&lt;0.001). In the pre-BAV-TAVI group only, at NCC, an upward migration decreased the ID from stage-2 to stage-3 (p=0.022). PVR ≥grade 2, immediately after expansion was more frequently observed in pre-BAV-TAVI group (41% vs 22%, respectively; p=0.024). However, PVR was similar at discharge. Clinical parameters were comparable between the two groups.

CONCLUSIONS: The use of BAV prior to TAVI may have an impact on device final position, but not on short- and long-term clinical outcome.</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/27177535?dopt=Abstract</style></custom1></record></records></xml>